440 related articles for article (PubMed ID: 23832962)
1. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
4. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1.
Lavery GG; Zielinska AE; Gathercole LL; Hughes B; Semjonous N; Guest P; Saqib K; Sherlock M; Reynolds G; Morgan SA; Tomlinson JW; Walker EA; Rabbitt EH; Stewart PM
Endocrinology; 2012 Jul; 153(7):3236-48. PubMed ID: 22555437
[TBL] [Abstract][Full Text] [Related]
5. Liver-selective transgene rescue of hypothalamic-pituitary-adrenal axis dysfunction in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Paterson JM; Holmes MC; Kenyon CJ; Carter R; Mullins JJ; Seckl JR
Endocrinology; 2007 Mar; 148(3):961-6. PubMed ID: 17170103
[TBL] [Abstract][Full Text] [Related]
6. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
7. 11β-HSD1 contributes to age-related metabolic decline in male mice.
Morgan SA; Gathercole LL; Hassan-Smith ZK; Tomlinson J; Stewart PM; Lavery GG
J Endocrinol; 2022 Dec; 255(3):117-129. PubMed ID: 36205523
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
9. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Paterson JM; Morton NM; Fievet C; Kenyon CJ; Holmes MC; Staels B; Seckl JR; Mullins JJ
Proc Natl Acad Sci U S A; 2004 May; 101(18):7088-93. PubMed ID: 15118095
[TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11β-HSD1 and H6PDH.
Abrahams L; Semjonous NM; Guest P; Zielinska A; Hughes B; Lavery GG; Stewart PM
J Endocrinol; 2012 Sep; 214(3):367-72. PubMed ID: 22718432
[TBL] [Abstract][Full Text] [Related]
13. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
14. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
16. Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
Morgan SA; Berryman DE; List EO; Lavery GG; Stewart PM; Kopchick JJ
Growth Horm IGF Res; 2022 Feb; 62():101440. PubMed ID: 34814007
[TBL] [Abstract][Full Text] [Related]
17. Regulation of 11beta-hydroxysteroid dehydrogenase type 1 and glucose-stimulated insulin secretion in pancreatic islets of Langerhans.
Ortsäter H; Alberts P; Warpman U; Engblom LO; Abrahmsén L; Bergsten P
Diabetes Metab Res Rev; 2005; 21(4):359-66. PubMed ID: 15586384
[TBL] [Abstract][Full Text] [Related]
18. Genistein inhibits glucocorticoid amplification in adipose tissue by suppression of 11β-hydroxysteroid dehydrogenase type 1.
Tagawa N; Kubota S; Kobayashi Y; Kato I
Steroids; 2015 Jan; 93():77-86. PubMed ID: 25447798
[TBL] [Abstract][Full Text] [Related]
19. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
20. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue.
Wang Y; Yan C; Liu L; Wang W; Du H; Fan W; Lutfy K; Jiang M; Friedman TC; Liu Y
Am J Physiol Endocrinol Metab; 2015 Jan; 308(1):E84-95. PubMed ID: 25389364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
